Manuscripts

Search by keyword, year, or author name.

Showing 1591 manuscripts.

Human b-defensin-3 activates professional antigen-presenting cells via toll-like receptors 1 and 2

Nicholas T. Funderburg, Ph.D., Michael M. Lederman, M.D., Zhimin Feng, Michael G. Drage, Julie Jadlowsky, Clifford V. Harding, Scott F. Sieg, Ph.D. Human b-defensin-3 activates professional antigen-presenting cells via toll-like receptors 1 and 2. Proceedings of the National Academy of Sciences of the United States of America. 2007 Nov 20; 104(47):18631-5.

Year

2007

Journal

Proceedings of the National Academy of Sciences of the United States of America

Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration

Edward R. Cachay, M.D., Niousha Moini, Sergei L. Kosakovsky Pond, Ph.D., Rick L. Pesano, M.D., Ph.D., Yolanda Lie, Heidi Aiem, David M. Butler, M.D., Scott L. Letendre, M.D., W. Christopher Mathews, M.D., M.S.P.H., Davey M. Smith, M.D. Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration. The Open AIDS Journal. 2007 Oct 27; 1:5-10.

Year

2007

Journal

The Open AIDS Journal

Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic-pharmacodynamic analysis

Susan L Rosenkranz, Ph.D., Kevin E. Yarasheski, Ph.D., Michael F. Para, M.D., Richard C. Reichman, M.D., Gene D. Morse, Pharm.D. Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic-pharmacodynamic analysis. Metabolic Syndrome and Related Disorders. 2007 Jun 01; 5(2):163-73.

Year

2007

Journal

Metabolic Syndrome and Related Disorders

Reproductive health of adolescent girls perinatally infected with HIV.

Susan Brogly, Ph.D., Heather D. Watts, M.D., Nathalie Ylitalo, M.D., Ph.D., E. L. Franco, George Seage, III, Sc.D., M.P.H., James M. Oleske, M.D., Michelle L. Eagle, P.A.-C., Russell B. Van Dyke, M.D. Reproductive health of adolescent girls perinatally infected with HIV. American Journal of Public Health. 2007 Jun 01; 97(6):1047-1052. PMID: 17463385; PMCID: PMC1874205.

Year

2007

Journal

American Journal of Public Health

Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.

Akihiko Saitoh, M.D., Courtney V. Fletcher, Pharm.D., Richard Brundage, Pharm.D., Ph.D., Carmelita Alvero, Terence Fenton, Ed.D., Karen Hsia, Ph.D., Stephen A. Spector, M.D. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. Journal of Acquired Immune Deficiency Syndromes. 2007 Jul 01; 45(3):280 - 285. PMID: 17356468.

Year

2007

Journal

Journal of Acquired Immune Deficiency Syndromes

Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.

Carmen D. Zorrilla, M.D., Russell B. Van Dyke, M.D., Arlene D. Bardeguez, M.D., M.P.H., F.A.C.O.G., Edward P. Acosta, Pharm.D., Elizabeth (Betsy) Smith, M.D., Michael Hughes, Ph.D., Sharon Huang, M.S., Heather D. Watts, M.D., Barbara E. Heckman, B.S., Barbara E. Heckman, B.S., Eleanor Jimenez, M.D., F.A.A.P., George D. McSherry, M.D., Lynne M. Mofenson, M.D., F.A.A.P. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. Antimicrobial Agents and Chemotherapy. 2007 Jun 01; 51(6):2208 - 2210. PMID: 17420209; PMCID: PMC1891372.

Year

2007

Journal

Antimicrobial Agents and Chemotherapy

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels. Results of a prospective randomized trial (AIDS clinical trial group 5125s)

Pablo Tebas, M.D., Jiameng Zhang, Ph.D., Kevin E. Yarasheski, Ph.D., Scott Evans, Ph.D., Margaret A. Fischl, M.D., Abby Helen Shevitz, M.D., M.P.H., Judith Feinberg, M.D., Ann C. Collier, M.D., Cecilia M. Shikuma, M.D., Barbara Brizz, M.H.S.Ed., B.S.N., Fred Richard Sattler, M.D. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels. Results of a prospective randomized trial (AIDS clinical trial group 5125s). Journal of Acquired Immune Deficiency Syndromes. 2007 Jun 01; 45(2):193-200.

Year

2007

Journal

Journal of Acquired Immune Deficiency Syndromes

Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: a cross-protocol analysis

Nancy Radcliffe Reynolds, Ph.D., Junfeng Sun, Haikady N. Nagaraja, Ph.D., Allen L. Gifford, M.D., Albert W. Wu, M.D., M.P.H., Margaret A. Chesney, Ph.D. Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: a cross-protocol analysis. Journal of Acquired Immune Deficiency Syndromes. 2007 Dec 01; 46(4):402-9.

Year

2007

Journal

Journal of Acquired Immune Deficiency Syndromes

Phase 2 study of the safety and efficacy of Vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211

Roy (Trip) Gulick, M.D., M.P.H., Zhaohui Su, Ph.D., Charles Flexner, M.D., Michael Hughes, Ph.D., Paul Skolnik, M.D., Timothy J. Wilkin, M.D., M.P.H., Robert Gross, M.D., M.S.C.E., Amy Krambrink, M.S., Eoin Coakley, M.D., Wayne Greaves, M.D., Andrew R. Zolopa, M.D., Richard C. Reichman, M.D., Catherine Godfrey, M.D., Martin S. Hirsch, M.D., Daniel R. Kuritzkes, M.D. Phase 2 study of the safety and efficacy of Vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. Journal of Infectious Diseases. 2007 Jul 15; 196(2):304-12.

Year

2007

Journal

Journal of Infectious Diseases